Mylan To Pay $4 Bil. For King Ahead Of Launch Of Beta Blocker Nebivolol
This article was originally published in The Pink Sheet Daily
Executive Summary
The company cites King’s 1,200-person sales force as one reason behind the acquisition. King’s cardiovascular marketing experience with the ACE inhibitor Altace will be beneficial as Mylan anticipates approval for its beta blocker nebivolol.
You may also be interested in...
Mylan's Nebivolol Is "Approvable" At FDA
The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.
Mylan's Nebivolol Is "Approvable" At FDA
The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.
Mylan Reaffirms Commitment To Brand Business Growth Despite King Setback
The company will continue to explore acquisition opportunities, CEO Coury says, noting King was not "the only option." Mylan is not yet discussing whether it will launch and market nebivolol on its own or seek a partner for the cardiovascular agent; J&J holds a "right to consent" to any partner.